Please ensure Javascript is enabled for purposes of website accessibility

Will 2016 Be Express Scripts' Worst Year Yet?

By Keith Speights - Jan 25, 2016 at 9:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With its largest customer threatening to leave, the country's biggest PBM could be in for a rotten year.

Image Source: Charles Williams on Flickr.

Last year was blah for Express Scripts Holding Company (ESRX) shareholders. The giant pharmacy benefit manager's stock turned in 3% gain -- well below the 21% jump from the previous year. After just a few weeks of the New Year, though, investors might already be nostalgic for blah. Express Scripts shares have plunged over 14% in January so far. Could 2016 be the PBM's worst year yet?

A bad case of the blues
It only took a few minutes to turn 2016 into a very unhappy New Year for Express Scripts. Joseph Swedish, CEO of Anthem (ELV -0.59%), spoke on Jan. 12 at the J.P. Morgan Healthcare Conference. The last portion of his presentation focused on the contract between Anthem, which operates Blue Cross and Blue Shield plans in 14 states, and Express Scripts.

Anthem sold its internal PBM to Express Scripts in 2009 and signed a 10-year contract. The agreement contained a provision that allowed for repricing effective Dec. 1, 2015. Talks about this repricing have hit a major obstacle: Anthem wants savings of around $3 billion per year -- and Express Scripts is balking at that amount.

From Anthem's perspective, Express Scripts has been pocketing significant savings that it has made from negotiating with pharmaceutical companies. Express Scripts doesn't have an issue with a pricing review, but the PBM thinks the amount floated by Anthem isn't justified.

Potential fallout
What would it mean if the two sides don't come to an agreement? Anthem could try to find another PBM. If the dispute ends in a parting of ways, it would be a huge blow for Express Scripts. Anthem is the company's largest customer, making up 14% of Express Scripts' revenue in 2014.

But there's also an enormous impact if Express Scripts gives Anthem what it's asking for. In December, Express Scripts announced its 2016 financial guidance. That guidance called for earnings before interest, taxes, depreciation, and amortization (EBITDA) of $7.23 billion to $7.43 billion. Paying out $3 billion more to Anthem would wreak havoc on that forecast.

Of course, there's still a chance that the two companies reach a compromise solution. Even if they settle, it seems likely that Express Scripts will see lower earnings than it expected for 2016. On the positive side, Express Scripts could benefit over the long run if Anthem ultimately renews the contract with Express Scripts and swings Cigna's (CI) business its way. Anthem announced that it would buy Cigna in July 2015. However, Cigna is locked into a contract with Catamaran, which is now part of UnitedHealth's (UNH 0.00%) OptumRx, until 2023. 

Worst year ever?
What would it take for 2016 to be the worst year ever for Express Scripts? In 2008, the PBM's stock plunged nearly 25%. The Anthem debacle has caused Express Scripts shares to fall nearly half that amount in a matter of days.

Whether this year becomes the worst yet for Express Scripts depends largely on the outcome of the Anthem contract negotiations. I don't see Express Scripts ponying up $3 billion -- nearly half of its expected 2016 EBITDA. As important as Anthem's business is, that's too hefty a price tag.

However, I also think it's in Anthem's best interest to strike a deal. There aren't many PBMs that could handle its size -- and one of them is owned by UnitedHealth, a direct competitor of Anthem. Maybe Anthem's long-term strategy is to create its own PBM, but that takes time and would be tricky to pull off with a simultaneous acquisition of Cigna. There's also the question of whether any PBM would agree to the pricing that Anthem wants. 

My view is that 2016 could very well be the worst yet for Express Scripts -- but only if the overall market enters serious bear territory and not solely because of the Anthem situation. After all, Express Scripts' stock has already fallen roughly the same percentage as the amount of revenue that the PBM generates from the Anthem business. The bad news over the potential loss of this contract seems to already be baked into Express Scripts' share price. That might be the best news to be found for Express Scripts investors right now.

Keith Speights owns shares of Express Scripts. The Motley Fool owns shares of and recommends Express Scripts. The Motley Fool recommends Anthem and UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Express Scripts Holding Company Stock Quote
Express Scripts Holding Company
ESRX
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
UNH
$545.01 (0.00%) $0.01
Elevance Health Inc. Stock Quote
Elevance Health Inc.
ELV
$487.96 (-0.59%) $-2.89
Cigna Corporation Stock Quote
Cigna Corporation
CI

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
395%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.